Low dose ET019002- T Cells
XJTU1AF2018LSL-C003
Phase 1 mab active
Quick answer
Low dose ET019002- T Cells for B-Cell Malignancies is a Phase 1 program (mab) at First Tracks Biotherapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- First Tracks Biotherapeutics
- Indication
- B-Cell Malignancies
- Phase
- Phase 1
- Modality
- mab
- Status
- active